Advanced Solid Tumors Clinical Trials in Nashville, Tennessee
9 recruitingNashville, Tennessee
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.188 enrolled9 locationsNCT06835569
Recruiting
Phase 2
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 1
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Ovarian CancerAdvanced Solid TumorsBreast Cancer Recurrent+1 more
Accent Therapeutics90 enrolled5 locationsNCT06799065
Recruiting
Phase 1
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pancreatic CancerColon CancerAdvanced Cancer+2 more
Pheon Therapeutics165 enrolled7 locationsNCT07127874
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Advanced Solid Tumors
DualityBio Inc.862 enrolled107 locationsNCT05914116
Recruiting
Phase 1Phase 2
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.754 enrolled16 locationsNCT05379985
Recruiting
Phase 1Phase 2
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Advanced Solid Tumors
LigaChem Biosciences, Inc.300 enrolled8 locationsNCT05941507
Recruiting
Phase 1
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Breast CancerAdvanced CancerAdvanced Solid Tumors+1 more
OnKure, Inc.200 enrolled34 locationsNCT06239467
Recruiting
Phase 1Phase 2
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626